ProCE Banner Activity

neoHIP: Phase II Trial of Neoadjuvant Pembrolizumab + HER2-Targeted Therapy for HER2-Positive Early Breast Cancer

Conference Coverage
Slideset

The neoHIP phase II study showed that adding pembrolizumab to dual HER2-targeted neoadjuvant therapy was safe and improved pathologic compete response in patients with HER2+ early breast cancer.

Released: December 17, 2024

Expiration: June 16, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Lilly, Merck Sharp & Dohme LLC, and Novartis Pharmaceuticals Corporation.

Lilly

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation